Furthermore, conducting mechanistic studies to elucidate the interplay between the PPARG pathway and pathological processes like inflammation and cortisol synthesis would provide a more comprehensive understanding of rosiglitazone’s application as a therapy for CS. The gene discussed is PPARG; the disease is Cowden syndrome 1.